VAN-ZOLMITRIPTAN ODT TABLET (ORALLY DISINTEGRATING)

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

ZOLMITRIPTAN

Disponible desde:

VANC PHARMACEUTICALS INC

Código ATC:

N02CC03

Designación común internacional (DCI):

ZOLMITRIPTAN

Dosis:

2.5MG

formulario farmacéutico:

TABLET (ORALLY DISINTEGRATING)

Composición:

ZOLMITRIPTAN 2.5MG

Vía de administración:

ORAL

Unidades en paquete:

2X3

tipo de receta:

Prescription

Área terapéutica:

SELECTIVE SEROTONIN AGONISTS

Resumen del producto:

Active ingredient group (AIG) number: 0134381001; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2019-08-07

Ficha técnica

_VAN- Zolmitriptan ODT _
_Page 1 of 32_
PRODUCT MONOGRAPH
PR
VAN-ZOLMITRIPTAN ODT
Zolmitriptan Orally Disintegrating Tablets
2.5 mg
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
MANUFACTURER AND DISTRIBUTOR:
DATE OF PREPARATION: MARCH 25, 2015
Vanc Pharmaceuticals Inc.
Unit-210, 2639 Viking Way
Richmond, BC V6V 3B7
www.vancpharm.com
SUBMISSION CONTROL NO.: 182332
_VAN- Zolmitriptan ODT _
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................. 3
SUMMARY PRODUCT
INFORMATION.....................................................................
3
INDICATIONS AND CLINICAL
USE............................................................................
3
CONTRAINDICATIONS..................................................................................................
3
WARNINGS AND
PRECAUTIONS................................................................................
4
ADVERSE
REACTIONS..................................................................................................
10
DRUG
INTERACTIONS..................................................................................................
15
DOSAGE AND
ADMINISTRATION..............................................................................
16
OVERDOSAGE.................................................................................................................
17
ACTION AND CLINICAL
PHARMACOLOGY.............................................................
18
STORAGE AND
STABILITY..........................................................................................
20
DOSAGE FORMS, COMPOSITION AND
PACKAGING.............................................
20
PART II: SCIENTIFIC
INFORMATION.........................................................................
21
PHARMACEUTICAL
INFORMATION..........................................................................
21
CLINICAL
TRIALS..........................................................................................................
2